Again, no inhibitory effect of PDS-0330, used alone or in combination with IM, was observed in GIST 430 cells (Supplementary Figure S3B), suggesting that the increased expression of CLDN1 in IM-resistant GIST is a promising molecular target for personalized therapy in GIST. This evidence concerns the gene CLDN1 and gastrointestinal stromal tumor.